Systematic review of the role of calprotectin in cirrhosis.
bacterial translocation
biomarker
calprotectin
cirrhosis
hepatic encephalopathy
spontaneous bacterial peritonitis
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
17 Oct 2023
17 Oct 2023
Historique:
revised:
16
09
2023
received:
17
05
2023
accepted:
23
09
2023
medline:
18
10
2023
pubmed:
18
10
2023
entrez:
18
10
2023
Statut:
aheadofprint
Résumé
Calprotectin is a calcium-binding-S100-protein synthetized mainly in neutrophils which has been demonstrated to be an accurate biomarker of the presence of these cells. Gut barrier dysfunction in patients with advanced chronic liver disease (ACLD), in addition to the lack of noninvasive tools for diagnosis and prognosis of cirrhosis decompensations, has raised interest in this biomarker. Our aim is to summarize the current evidence regarding the role of calprotectin in terms of its diagnostic and prognostic utility in ACLD. We performed a systematic search (PROSPERO registration no. CRD42023389069) of original articles published without any restrictions on the publication date until January 2023 providing information about calprotectin for the prognosis or diagnosis of ACLD and its decompensations in adult patients. A total 227 articles were identified, and 26 observational studies finally met the inclusion criteria. In 14 studies, calprotectin was measured in ascitic fluid, all of which reported higher calprotectin values in spontaneous bacterial peritonitis, while cut-off points for its diagnosis were proposed in nine studies. Three studies reported higher faecal calprotectin levels in patients with hepatic encephalopathy and portal hypertension. Four studies evaluated faecal calprotectin and one plasma calprotectin as biomarkers for gut barrier integrity and bacterial translocation. Calprotectin is emerging as a promising biomarker in ACLD, particularly for the management of bacterial infections and alcohol-related liver disease. Further research with better study designs should help to determine the feasibility of calprotectin measurement in routine clinical practice.
Sections du résumé
BACKGROUND
BACKGROUND
Calprotectin is a calcium-binding-S100-protein synthetized mainly in neutrophils which has been demonstrated to be an accurate biomarker of the presence of these cells. Gut barrier dysfunction in patients with advanced chronic liver disease (ACLD), in addition to the lack of noninvasive tools for diagnosis and prognosis of cirrhosis decompensations, has raised interest in this biomarker.
AIMS
OBJECTIVE
Our aim is to summarize the current evidence regarding the role of calprotectin in terms of its diagnostic and prognostic utility in ACLD.
METHODS
METHODS
We performed a systematic search (PROSPERO registration no. CRD42023389069) of original articles published without any restrictions on the publication date until January 2023 providing information about calprotectin for the prognosis or diagnosis of ACLD and its decompensations in adult patients.
RESULTS
RESULTS
A total 227 articles were identified, and 26 observational studies finally met the inclusion criteria. In 14 studies, calprotectin was measured in ascitic fluid, all of which reported higher calprotectin values in spontaneous bacterial peritonitis, while cut-off points for its diagnosis were proposed in nine studies. Three studies reported higher faecal calprotectin levels in patients with hepatic encephalopathy and portal hypertension. Four studies evaluated faecal calprotectin and one plasma calprotectin as biomarkers for gut barrier integrity and bacterial translocation.
CONCLUSIONS
CONCLUSIONS
Calprotectin is emerging as a promising biomarker in ACLD, particularly for the management of bacterial infections and alcohol-related liver disease. Further research with better study designs should help to determine the feasibility of calprotectin measurement in routine clinical practice.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14111Subventions
Organisme : Instituto de Salud Carlos III
ID : PI19/00523
Informations de copyright
© 2023 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.
Références
Jukic A, Bakiri L, Wagner EF, Tilg H, Adolph TE. Calprotectin: from biomarker to biological function. Gut. 2021;1:1-11. doi:10.1136/gutjnl-2021-324855
Poullis A, Foster R, Mendall MA, Fagerhol MK. Emerging role of calprotectin in gastroenterology. J Gastroenterol Hepatol. 2003;18(7):756-762. doi:10.1046/j.1440-1746.2003.03014.x
Guardiola J, Cerrillo E, Gisbert JP, Esteve M. Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la utilidad de la determinación de calprotectina fecal en la enfermedad inflamatoria intestinal. Gastroenterol Hepatol. 2018;41(8):514-529. doi:10.1016/j.gastrohep.2018.05.029
Teh CSJ, Suhaili Z, Lim KT, et al. The value of calprotectin in synovial fluid for the diagnosis of chronic prosthetic joint infection. Bone Jt Res. 2020;9(8):450-456. doi:10.1302/2046-3758.98.BJR-2019-0329.R
D'Amico F, Rubin DT, Kotze PG, et al. International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. United Eur Gastroenterol J. 2021;9(4):451-460. doi:10.1002/ueg2.12069
Riva A, Gray EH, Azarian S, et al. Faecal cytokine profiling as a marker of intestinal inflammation in acutely decompensated cirrhosis. JHEP Rep. 2020;2(6):100151. doi:10.1016/j.jhepr.2020.100151
de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII-renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959-974. doi:10.1016/j.jhep.2021.12.022
Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality if Nonrandomized Studies in Meta-Analyses. 2023. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm
Abdel-Razik A, Mousa N, Elhammady D, et al. Ascitic fluid calprotectin and serum procalcitonin as accurate diagnostic markers for spontaneous bacterial peritonitis. Gut Liver. 2016;10(4):624-631. doi:10.5009/gnl15120
Burri E, Schulte F, Muser J, Meier R, Beglinger C. Measurement of calprotectin in ascitic fluid to identify elevated polymorphonuclear cell count. World J Gastroenterol. 2013;19(13):2028-2036. doi:10.3748/wjg.v19.i13.2028
Selim FO, El-Deeb NA, Farrag HA, Ahmed AM. Assessment of calprotectin in ascitic fluid as a marker for spontaneous bacterial peritonitis diagnosis in cirrhotic patients. Egypt J Intern Med. 2018;30(4):223-230. doi:10.4103/ejim.ejim_17_18
Fernandes SR, Santos P, Fatela N, et al. Ascitic calprotectin is a novel and accurate marker for spontaneous bacterial peritonitis. J Clin Lab Anal. 2016;30(6):1139-1145. doi:10.1002/jcla.21994
Gad M, EL-Shewi M, Sabry J, Zawawy A. Role of calprotectin in diagnosis of spontaneous bacterial peritonitis in cirrhotic patients with ascites. Afro-Egypt J Infect Endem Dis. 2015;5(4):226-234. doi:10.21608/aeji.2015.17843
Heikl AA, El-Nokeety MM, Roshdy E, Mohey A. Ascitic calprotectin as a diagnostic marker for spontaneous bacterial peritonitis in hepatitis C virus cirrhotic Egyptian patients. Egypt J Intern Med. 2018;30(1):1-7. doi:10.4103/ejim.ejim_41_17
Weil D, Heurgue-Berlot A, Monnet E, et al. Accuracy of calprotectin using the Quantum Blue Reader for the diagnosis of spontaneous bacterial peritonitis in liver cirrhosis. Hepatol Res. 2019;49(1):72-81. doi:10.1111/hepr.13239
Nabiel Y, Barakat G, Abed S. Serum CD64 and ascitic fluid calprotectin and microRNA-155 as potential biomarkers of spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol. 2019;31(8):1064-1069. doi:10.1097/MEG.0000000000001443
Lutz P, Pfarr K, Nischalke HD, et al. The ratio of calprotectin to total protein as a diagnostic and prognostic marker for spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites. Clin Chem Lab Med. 2015;53(12):2031-2039. doi:10.1515/cclm-2015-0284
Makhlouf NA, Morsy KH, Mahmoud AA, Hassaballa AE. Diagnostic value of ascitic fluid lactoferrin, calprotectin, and calprotectin to albumin ratio in spontaneous bacterial peritonitis. Int J Curr Microbiol Appl Sci. 2018;7(2):2618-2631. doi:10.20546/ijcmas.2018.702.319
Nasereslami M, Khamnian Z, Moaddab Y, Jalali Z. Diagnostic and prognostic role of ascitic fluid calprotectin level: six-month outcome findings in cirrhotic patients. Scand J Gastroenterol. 2020;55(9):1093-1098. doi:10.1080/00365521.2020.1794023
Josifovikj FL, Stardelova KG, Todorovska B, et al. Diagnostic potential of calprotectin for spontaneous bacterial peritonitis in patients withliver cirrhosis and ascites. Prilozi. 2021;42(3):97-106. doi:10.2478/prilozi-2021-0040
Abdel-Razik A, Abdelsalam M, Gad DF, et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: novel predictors. Eur J Gastroenterol Hepatol. 2020;32:718-726. doi:10.1097/MEG.0000000000001578
Helmy A, El Saady A, Khayyal SM, et al. Serum calprotectin as a non-invasive diagnostic marker for spontaneous bacterial peritonitis in Egyptian cirrhotic patients. J Med Sci Clin Res. 2016;4(7):11177-11188. doi:10.18535/jmscr/v4i7.01
Elnaggar YA, Zidan HE, Abdelbaky EM, Wadea FM. Association of Increased Fecal Calprotectin levels with hepatic encephalopathy and spontaneous peritonitis in Egyptian cirrhotic patients. J Gastroenterol Hepatol Res. 2020;9(3):3217-3222. doi:10.17554/j.issn.2224-3992.2020.09.925
Gundling F, Schmidtler F, Hapfelmeier A, et al. Fecal calprotectin is a useful screening parameter for hepatic encephalopathy and spontaneous bacterial peritonitis in cirrhosis. Liver Int. 2011;31(9):1406-1415. doi:10.1111/j.1478-3231.2011.02577.x
Tokmak S, Harmanci ÖA. Elevated levels of fecal calprotectin in cirrhotic patients and spontaneous bacterial peritonitis. Duzce Med J. 2019;21(3):214-217. doi:10.18678/dtfd.653549
Alempijević T, Štulić M, Popovic D, Culafic D, Dragasevic S, Milosavljevic T. The role of fecal calprotectin in assessment of hepatic encephalopathy in patients with liver cirrhosis. Acta Gastroenterol Belg. 2014;77(3):302-305.
Yagmur E, Schnyder B, Scholten D, et al. Erhöhte konzentrationen von fäkalem calprotectin bei patienten mit leberzirrhose. Dtsch Medizinische Wochenschrift. 2006;131(36):1930-1934. doi:10.1055/s-2006-949189
Homann C, Garred P, Graudal N, et al. Plasma calprotectin: a new prognostic marker of survival in alcohol-induced cirrhosis. Hepatology. 1995;21(4):979-985. doi:10.1016/0270-9139(95)90244-9
Blesl A, Jüngst C, Lammert F, et al. Secondary sclerosing cholangitis in critically ill patients alters the gut-liver axis: a case control study. Nutrients. 2020;12(9):2728. doi:10.3390/nu12092728
Header DA, Ellakany WI, Ellakany AI. El nivel de calprotectina fecal como marcador de várices esofágicas en pacientes egipcios cirróticos por VHC. Rev Gastroenterol México. 2022. doi:10.1016/j.rgmx.2021.11.009
Homann C, Christensen E, Schlichting P, Philipsen EK, Graudal NA, Garred P. Ascites fluid and plasma calprotectin concentrations in liver disease. Scand J Gastroenterol. 2003;38(4):415-420. doi:10.1080/00365520310000870
Prystupa A, Kiciński P, Luchowska-kocot D. Analysis of novel serum markers of fibrosis and angiogenesis in patients with alcoholic liver cirrhosis. Ann Agric Environ Med. 2020;27(4):568-573. doi:10.26444/aaem/127621
Matiollo C, Rateke ECM, Moura EQA, et al. Elevated calprotectin levels are associated with mortality in patients with acute decompensation of liver cirrhosis. World J Hepatol. 2022;14(11):1964-1976. doi:10.4254/wjh.v14.i11.1964
Koutsounas I, Kaltsa G, Siakavellas SI, Bamias G. Markers of bacterial translocation in end-stage liver disease. World J Hepatol. 2015;7(20):2264-2273. doi:10.4254/wjh.v7.i20.2264
Turco L, Garcia-Tsao G. Portal hypertension: pathogenesis and diagnosis. Clin Liver Dis. 2019;23(4):573-587. doi:10.1016/j.cld.2019.07.007
van der Merwe S, Chokshi S, Bernsmeier C, Albillos A. The multifactorial mechanisms of bacterial infection in decompensated cirrhosis. J Hepatol. 2021;75:S82-S100. doi:10.1016/j.jhep.2020.11.029
Cohen MJ, Sahar T, Benenson S, Elinav E, Brezis M, Soares-Weiser K. Antibiotic prophylaxis for spontaneous bacterial peritonitis in cirrhotic patients with ascites, without gastro-intestinal bleeding. Cochrane Database Syst Rev. 2009;2:CD004791. doi:10.1002/14651858.CD004791.pub2
Angeli P, Bernardi M, Villanueva C, et al. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460. doi:10.1016/j.jhep.2018.03.024
Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol. 2014;61(3):642-659. doi:10.1016/j.jhep.2014.05.042
Montagnese S, Rautou PE, Romero-Gómez M, et al. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy. J Hepatol. 2022;77(3):807-824. doi:10.1016/j.jhep.2022.06.001
Costa D, Simbrunner B, Jachs M, et al. Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality. J Hepatol. 2021;74(4):819-828. doi:10.1016/j.jhep.2020.10.004
D'Amico G, Morabito A, D'Amico M, et al. Clinical states of cirrhosis and competing risks. J Hepatol. 2018;68(3):563-576. doi:10.1016/j.jhep.2017.10.020
Stankevic E, Israelsen M, Juel HB, et al. Binge drinking episode causes acute, specific alterations in systemic and hepatic inflammation-related markers. Liver Int. 2023:1-12. doi:10.1111/liv.15692
Bourgonje AR, van den Berg EH, Kieneker LM, et al. Plasma calprotectin levels associate with suspected metabolic-associated fatty liver disease and all-cause mortality in the general population. Int J Mol Sci. 2022;23(24):15708. doi:10.3390/ijms232415708
Kido J, Hayashi N, Kataoka M, Shinohara Y, Nagata T. Norepinephrine stimulates calprotectin expression in human monocytic cells. J Periodontal Res. 2006;41(3):159-164. doi:10.1111/j.1600-0765.2005.00845.x